MAximising Therapeutic Utility in Rheumatoid Arthritis  

Highlights and News

Disease activity and treatment response in early rheumatoid arthritis: an exploratory metabolomic profiling in the NORD-STAR cohort - Arthritis Research & Therapy
Disease activity and treatment response in early rheumatoid arthritis: an exploratory metabolomic profiling in the NORD-STAR cohort  Arthritis Research & Therapy
Deep molecular profiling of synovial biopsies in the STRAP trial identifies signatures predictive of treatment response to biologic therapies in rheumatoid arthritis - Nature
Deep molecular profiling of synovial biopsies in the STRAP trial identifies signatures predictive of treatment response to biologic therapies in rheumatoid arthritis  Nature
Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials - The Lancet
Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials  The Lancet
Deciphering the molecular landscape of rheumatoid arthritis offers new insights into the stratified treatment for the condition - Frontiers
Deciphering the molecular landscape of rheumatoid arthritis offers new insights into the stratified treatment for the condition  Frontiers
Computational approaches in rheumatic diseases - Deciphering complex spatio-temporal cell interactions - ScienceDirect.com
Computational approaches in rheumatic diseases - Deciphering complex spatio-temporal cell interactions  ScienceDirect.com
TOFA-PREDICT study protocol: a stratification trial to determine key immunological factors predicting tofacitinib efficacy and drug-free remission in psoriatic arthritis (PsA) - BMJ Open
TOFA-PREDICT study protocol: a stratification trial to determine key immunological factors predicting tofacitinib efficacy and drug-free remission in psoriatic arthritis (PsA)  BMJ Open
Is There a Missing Link in Rheumatoid Arthritis Management? - European Medical Journal
Is There a Missing Link in Rheumatoid Arthritis Management?  European Medical Journal
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial - Nature
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial  Nature
Towards stratified treatment of JIA: machine learning identifies subtypes in response to methotrexate from four UK cohorts - The Lancet
Towards stratified treatment of JIA: machine learning identifies subtypes in response to methotrexate from four UK cohorts  The Lancet
Clinical implications of synovial tissue phenotypes in rheumatoid arthritis - Frontiers
Clinical implications of synovial tissue phenotypes in rheumatoid arthritis  Frontiers
Location and amount of joint involvement differentiates rheumatoid arthritis into different clinical subsets - Nature
Location and amount of joint involvement differentiates rheumatoid arthritis into different clinical subsets  Nature
Precision medicine in psoriatic arthritis: how should we select targeted therapies? - The Lancet
Precision medicine in psoriatic arthritis: how should we select targeted therapies?  The Lancet
Synovial Tissue Heterogeneity in Rheumatoid Arthritis and Changes With Biologic and Targeted Synthetic Therapies to Inform Stratified Therapy - Frontiers
Synovial Tissue Heterogeneity in Rheumatoid Arthritis and Changes With Biologic and Targeted Synthetic Therapies to Inform Stratified Therapy  Frontiers
A longitudinal cohort study uncovers plasma protein biomarkers predating clinical onset and treatment response of rheumatoid arthritis - Nature
A longitudinal cohort study uncovers plasma protein biomarkers predating clinical onset and treatment response of rheumatoid arthritis  Nature
A Pauci-Immune Synovial Pathotype Predicts Inadequate Response to TNFα-Blockade in Rheumatoid Arthritis Patients - Frontiers
A Pauci-Immune Synovial Pathotype Predicts Inadequate Response to TNFα-Blockade in Rheumatoid Arthritis Patients  Frontiers
Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes - Nature
Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes  Nature
Addition of Fibroblast-Stromal Cell Markers to Immune Synovium Pathotypes Better Predicts Radiographic Progression at 1 Year in Active Rheumatoid Arthritis - Frontiers
Addition of Fibroblast-Stromal Cell Markers to Immune Synovium Pathotypes Better Predicts Radiographic Progression at 1 Year in Active Rheumatoid Arthritis  Frontiers
Automated multi-scale computational pathotyping (AMSCP) of inflamed synovial tissue - Nature
Automated multi-scale computational pathotyping (AMSCP) of inflamed synovial tissue  Nature
Utility of Baseline Transcriptomic Analysis of Rheumatoid Arthritis Synovium as an Indicator for Long-Term Clinical Outcomes - Frontiers
Utility of Baseline Transcriptomic Analysis of Rheumatoid Arthritis Synovium as an Indicator for Long-Term Clinical Outcomes  Frontiers
Systems-biology analysis of rheumatoid arthritis fibroblast-like synoviocytes implicates cell line-specific transcription factor function - Nature
Systems-biology analysis of rheumatoid arthritis fibroblast-like synoviocytes implicates cell line-specific transcription factor function  Nature
Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics - Nature
Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics  Nature
Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial - The Lancet
Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial  The Lancet
Persistence of Mast Cell-Positive Synovitis in Early Rheumatoid Arthritis Following Treatment With Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs - Frontiers
Persistence of Mast Cell-Positive Synovitis in Early Rheumatoid Arthritis Following Treatment With Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs  Frontiers
Clinical Applications of Synovial Biopsy - Frontiers
Clinical Applications of Synovial Biopsy  Frontiers

The MATURA consortium includes academic groups and industry partners working together to identify and test biomarkers
predictive of response to biological therapy in patients with rheumatoid arthritis
Home | Copyright © Experimental Medicine & Rheumatology Department, Queen Mary University London, 2015 - 2025 | Sitemap